After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerEli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced Share XAfter Scotland says no, NICE backs Lilly’s Retsevmo for lung cancerhttps://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/
ASH abstract drop backs Roche’s Polivy in first-line lymphomaRoche trumpeted a top-line results of the POLARIX trial of its Polivy therapy in previously-untreated B-cell lymphoma, and Share XASH abstract drop backs Roche’s Polivy in first-line lymphomahttps://pharmaphorum.com/news/ash-abstract-drop-backs-roches-polivy-in-first-line-lymphoma/
Roche, Blueprint’s RET cancer drug Gavreto cleared in EURoche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers, Share XRoche, Blueprint’s RET cancer drug Gavreto cleared in EUhttps://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/
NICE reaches a deal with Roche on access to oral SMA drug EvrysdiRoche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on Share XNICE reaches a deal with Roche on access to oral SMA drug Evrysdihttps://pharmaphorum.com/news/nice-reaches-a-deal-with-roche-on-access-to-oral-sma-drug-evrysdi/
Pfizer files oral COVID pill in US, signs access deal for 95 countriesArmed with impressive new data for its oral antiviral Paxlovid, Pfizer has filed for emergency use authorisation as Share XPfizer files oral COVID pill in US, signs access deal for 95 countrieshttps://pharmaphorum.com/news/pfizer-files-oral-covid-pill-in-us-signs-access-deal-for-95-countries/
COVID antibodies from Roche, Celltrion backed for approval in EUThe EMA’s human medicines committee has recommended approval of Roche’s Ronapreve and Celltrion’s Regkirona for use in COVID-19, Share XCOVID antibodies from Roche, Celltrion backed for approval in EUhttps://pharmaphorum.com/news/first-covid-antibodies-from-roche-celltrion-backed-in-eu/
Novartis finally sells Roche stake, for almost $21 billionAfter more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma Share XNovartis finally sells Roche stake, for almost $21 billionhttps://pharmaphorum.com/news/novartis-finally-sells-roche-stake-for-almost-21-billion/
Merck gets EU approval for Keytruda in triple-negative breast cancerMerck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form Share XMerck gets EU approval for Keytruda in triple-negative breast cancerhttps://pharmaphorum.com/news/merck-gets-eu-approval-for-keytruda-in-triple-negative-breast-cancer/
FDA clears Roche’s Susvimo implant for eye disease wet AMDRoche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration Share XFDA clears Roche’s Susvimo implant for eye disease wet AMDhttps://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/
